Aeterna Logo.png
AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT
12 mars 2020 08h00 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Logo.png
Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market
21 févr. 2020 14h00 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Logo.png
Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market
19 févr. 2020 19h00 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference
12 févr. 2020 08h05 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), specialty biopharmaceutical company commercializing and developing...
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin
28 janv. 2020 08h00 HE | Aeterna Zentaris Inc.
– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study P01 final study...
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing
27 janv. 2020 08h35 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing...
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement
08 janv. 2020 16h01 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC...
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris Announces Publication of GHD Management Guidelines
18 déc. 2019 09h00 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce that the American Association of Clinical Endocrinologists (AACE) and...
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris Announces 2020 Director Changes
16 déc. 2019 09h00 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce changes to its director composition planned for the first quarter of 2020....
AeternaZentarisLOGOJPG.jpg
Aeterna Zentaris Reports Third Quarter 2019 Financial and Operating Results
07 nov. 2019 18h28 HE | Aeterna Zentaris Inc.
CHARLESTON, S.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the third quarter ended September 30,...